Oneness Biotech Co., Ltd.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS carries a market capitalization of 788.06M, placing it among publicly traded companies globally. Its enterprise value stands at 633.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Oneness Biotech Co., Ltd. Sponsored GDR RegS's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS has 96.11M shares outstanding.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS trades at a trailing price-to-earnings ratio of 412.43. The price-to-sales ratio is 163.10, and the price-to-book ratio stands at 2.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 131.09 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 633.11M versus a market cap of 788.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS maintains a current ratio of 37.31, meaning it holds 37.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.39, indicating elevated leverage, while an interest coverage ratio of -54.61 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS posted a return on equity (ROE) of 0.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -5.89, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.53, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.56, useful for judging operating efficiency across full business cycles. The company generates approximately 25,554.06 in revenue per employee across its workforce of 189.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.88 indicates how many times Oneness Biotech Co., Ltd. Sponsored GDR RegS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS recorded 425,897.43 in income tax expense. That works out to an effective tax rate of 16.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.52M, leaving 1.91M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS's stock has declined approximately 28.16% over the past 52 weeks. The 50-day moving average sits at 7.31, while the 200-day moving average is 8.26.

Over the twelve months ended June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS generated 4.83M in revenue and converted that into 1.91M in net income, yielding earnings per share of 0.02. EBITDA reached -14.34M, while operating income came in at -24.76M.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS holds 170.57M in cash and equivalents against 11.06M in total debt, resulting in a net debt position of -11.35M. Total book value stands at 321.87M, with working capital of 176.57M providing operational flexibility.

Oneness Biotech Co., Ltd. Sponsored GDR RegS produced -5.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -627,304.42 in capital expenditures, free cash flow totaled -6.11M - equivalent to -0.06 per share.

Over the twelve months ended June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS posted a gross margin of 36.89, reflecting its pricing power and cost economics. The operating margin of -512.63 and net profit margin of 39.55 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.78: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Oneness Biotech Co., Ltd. Sponsored GDR RegS shareholders.

As of June 30, 2026, Oneness Biotech Co., Ltd. Sponsored GDR RegS has an Altman Z-Score of 17.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.